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Background: In Japan, people are negative towards life-prolonging treatments. Laws that regulate withholding
or discontinuing life-prolonging treatments and advance directives do not exist. Physicians, however, view
discontinuing life-prolonging treatments negatively due to fears of police investigations. Although ministerial guidelines
were announced regarding the decision process for end-of-life care in 2007, a consensus could not be reached on the
definition of end-of-life and conditions for withholding treatment. We established a forum for extended discussions
and consensus building on this topic.
Methods: We used the Neo-Socratic Dialogue (NSD) method which promotes philosophical discussion based on a
case-study to address a question and formulate a consensus and answer in a group. The question chosen for the
dialogue was: “What is a life-prolonging treatment?” A series of dialogues took place over a period of one and a half
days. It was carried out by three groups in 2010 and 2011. Seven participants with diverse backgrounds were
recruited per group. We analyzed the content of the discussion.
Results: Based on three case studies concerning different opinions about treatment options for an older
dementia patient, a patient demanding chemotherapy, and a severely ill neonate, conditions for futile life-prolonging
treatment were elucidated through NSD. Such treatments are those carried out for the sole purpose of prolonging life
and are detrimental to the patient, and should be decided based foremost on the patient’s lack of desire for treatment,
the consensus of those involved, and through social acceptance. These arguments are essentially consistent with ones
on medical futility in the United States. By expressing the objective of healthcare and the requirement of social
acceptance, participants were also able to elucidate issues related to the awareness of those involved and the
medical environment. Compared to the end-of-life guidelines in Japan, the objective of treatment, its effects, and
benefits were more specifically discussed with the patient’s intentions as the foremost consideration, rather than
being limited to the terminal stage.
Conclusions: This small study contributed to elucidating the conditions and current problems of futile life-prolonging
treatment through NSD. They would suggest more substantial guidelines and improvements on the administration of
the treatment.
Keywords: Life-prolonging treatment, Futility, Socratic Dialogue, Philosophical group discussion* Correspondence: aizawak@ncvc.go.jp
1Office for Research Ethics and Bioethics, Research and Development
Initiative Center, National Cerebral and Cardiovascular Center, 5-7-1
Fujishiro-dai, Suita-shi, Osaka 565-8565, Japan
Full list of author information is available at the end of the article
© 2013 Aizawa et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Aizawa et al. BMC Medical Ethics 2013, 14:51 Page 2 of 12
http://www.biomedcentral.com/1472-6939/14/51Background
Since the latter half of the 1970s, movements related to
euthanasia, death with dignity, and hospice care have
largely criticized life-prolonging treatments [1,2]. Indeed,
a survey conducted in 2008 by the Ministry of Health,
Labour, and Welfare (MHLW) regarding interest in end-
of-life care revealed that more than 70% of responses were
negative toward life-prolonging treatments when “death is
imminent within a few days,” “death is imminent in ap-
proximately 6 months,” “there is persistent disturbance of
consciousness,” or “the patient suffers from cerebrovascu-
lar disease or dementia.” [3] Against this backdrop, the
number of members of the Japan Society for Dying with
Dignity recently surpassed 120,000, or roughly 0.1% of the
Japanese population. The Society’s stance is to refuse life-
prolonging treatments that solely aim to delay death in
cases of incurable or terminal disease. In the event of
persistent disturbance of consciousness (i.e., persistent
vegetative state), they advocate the discontinuation of
life-support measures [4].
In 2005–2007, a number of cases involving the removal
of respiratory apparatuses were investigated by police and
widely reported by the media, although the charges were
later dropped [5]. These incidences prompted the MHLW
Investigation Committee to publicly announce guidelines
regarding the decision process for end-of-life care in 2007.
Despite these efforts, a consensus could not be reached on
the definition of “end-of-life” and criteria for discontinu-
ing treatment. Thus, final judgments and decisions are left
to the discretion of the healthcare team [6-8]. Al-
though laws that regulate withholding or discontinuing
life-prolonging treatments and advance directives do
not exist in Japan, physicians view discontinuing life-
prolonging treatments negatively due to fears of police
investigations. This situation underscores the need for
extended discussions on this topic. In other countries,
particularly the United States, medical futility and the
question of whether physicians should unilaterally
make decisions about withholding or discontinuing
life-prolonging treatments were being debated from
about 1990 [9]. Debates to this degree have yet to be
carried out in Japan [10].
Changes and diversification of public values lead to
the development of a wide range of views focused on the
basic objectives of healthcare. Few opportunities exist
for professionals and patients to discuss healthcare is-
sues and concerns. Nevertheless, these issues need to be
addressed with a particular focus on the future of Japan’s
healthcare system. Exploring these concerns is vital, and
efforts are needed to create and test a communication
model that aids in mutual understanding and consensus
building. The Neo-Socratic Dialogue (NSD) method can
be used in forums focused on issues, principles, and values
related to healthcare among participants of diversebackgrounds. In the present study, NSD was used to ad-
dress the question “what is a life-prolonging treatment?”
This small study contributed to elucidating the conditions
and current problems of futile life-prolonging treatment
through NSD.
Methods
NSD promotes philosophical dialogue among small groups
of approximately seven people. This method was formu-
lated by Leonard Nelson (1882–1927), and is presently
used in Germany, England, and Holland for philosophical
training, dialogue-based education, problem discovery, and
for establishing consensus [11,12]. In 1999, the method
was introduced in Japan and has been in use ever since.
Recent attempts have been made to apply NSD to ethical
and social discussions spanning the medical and healthcare
fields [13-17].
NSD typically starts with a general question. Each par-
ticipant then provides relevant case studies, and one is
selected for further investigation and discussion. Partici-
pants corroborate judgments and actions taken by those
involved in the selected case study, and abstract the
underlying principles and values. Finally, a consensus is
formulated around the initial question. To ensure the
success of any given dialogue, participants are asked to
conform to specific rules, which include speaking clearly
and listening carefully to other participants. Participants
are also provided with appropriate standards to help se-
lect a case study suitable for dialogue.
In the present study, a series of dialogues were divided
into six 90-minute sessions that took place over a period
of one and a half days. These sessions were carried out
by three groups in 2010 and 2011 in Tokyo, Osaka, and
Kumamoto, which are major cities in eastern, western,
and southern Japan. The general question chosen for the
dialogues was: “What is a life-prolonging treatment?”
While the term “life-prolonging treatment” is used in
herein, “life-prolonging therapy” and “life-prolongation”
were also used in the forums. Seven participants were
selected per group and recruited among acquaintances
of researchers that contributed to the study. The follow-
ing participants were enlisted in each group to illustrate
different standpoints on the question: two participants
representing the general public; an ethicist or bioethicist;
a participant with a legal background, a participant re-
presenting the mass media, or a sociologist; a physician;
a nurse; and an additional healthcare professional. When
a participant could not found, however, willing volunteers
from any background were invited. We also attempted to
recruit so that each group had at least three men and
three women. In addition, we anticipated that various types
of case studies would be selected and examined in the three
forums. During the discussions, a facilitator wrote the
main points on a flip chart, while a transcriber recorded
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cussions were also recorded on an IC recorder with partici-
pants' agreement to supplement these documents.
The content of the discussions were reviewed and ana-
lyzed from the following standpoints that had normally
been followed in NSD: what kinds of views were pre-
sented?; what were the reasons of the different views?;
what kinds of principles and values were revealed?; were
there any conflicts among them?; and what consensus
and answers were elucidated ?
This study was approved by a General Research Ethics
Review under the auspices of the Faculty of Medical and
Pharmaceutical Sciences at Kumamoto University (Eth-
ics No. 282 <modified>, issued March 31, 2010). Partici-
pants received written information about the study and
provided written informed consent to participate.Results
The total number of participants for the three forums
was 19, with a total of 40 case studies provided (see the
‘List of participants’ and ‘List of case studies’ sections).
The origin of the case studies included hospitals (24
cases), home (6), others (4), and unspecified (6).List of participants
Total participants for all three forums: 19 (5 men, 14
women)
The 1st forum (July 2010, Tokyo): 6 (1 man, 5 women)
Participants: 2 editors, lawyer, physician, 2 nurses
The 2nd forum (January 2011, Kumamoto): 6 (3 men, 3 women)
Participants: citizen (only on second day), bioethicist,
media representative, psychiatrist, nurse, pastor
The 3rd forum (February 2011, Osaka): 7 (1 man, 6 women)
Participants: citizen, ethicist, scientific writer, physician,
2 nurses, care managerList of case studies
40 case studies: palliative care (7 cases), treatment of eld-
erly (4), long-term artificial respiration (3), family requests
for treatment (3), family decisions (3), discussions among
family members (2), family care (2), cancer chemotherapy
(2), refusal of treatment (2), informed consent (1), advance
directive (1), DNAR order (1), treatment of severely ill
neonate (1), physicians’ flaunting of authority (1), family
burden (1), psychiatric disorder (1), medical journalism
(1), and pet euthanasia (1).The 1st NSD forum
Thirteen case studies were provided regarding the ques-
tion “What is a life-prolonging treatment?” The following
case was chosen to explore the meaning that various med-
ical treatments had for those involved in the case.Case 1: Differing opinions regarding the treatment of
elderly with dementia
Case source Resident physician
Summary One of my patients was a woman in her 90s
who suffered from dementia and valvular disease. She
lived with her eldest daughter, and her second daughter
lived away from home. The eldest daughter called the
hospital several times regarding the patient’s chest pain,
and after visiting the cardiovascular internal medicine
department, she was admitted to the hospital. At admis-
sion, she presented with a fever and poor respiratory sta-
tus. Complication by pneumonia was suspected. The
patient complained of pain and was in agony, but was
not competent to consent to treatment. The attending
physician at the cardiovascular department initiated
intravenous drip and diuretics to treat heart and respira-
tory failure, but did not use anti-microbials, which was
incomprehensible to me. On day 2 after admission, she
presented with arrhythmia (atrial fibrillation) and her
blood pressure decreased. Although an anti-arrhythmic
agent was administered, it was ineffective. Given the
state of emergency, defibrillation (DC) was attempted
once without obtaining consent from the family. Imme-
diately afterwards, the attending physician proposed Do
Not Attempt Resuscitation (DNAR) to the family be-
cause a full recovery was unlikely given the patient’s age,
as well as to prevent further pain from DC or artificial
respiration. The attending physician seemed to nega-
tively view life-prolonging treatments. Although the eld-
est daughter desired to prolong her mother’s life to the
greatest extent possible, the second daughter differed in
opinion, feeling sorry for her mother and not wanting
her to suffer any longer. Because the patient presented
with refractory arrhythmia, she was anesthetized to re-
lieve pain, and DC was continued while rapidly increas-
ing the voltage. At times, DC was carried out multiple
times a day, totaling about 20 times over the span of a
few days. Subsequently, intratracheal intubation was de-
cided against, but DC was continued and administration
of a strong anti-arrhythmic was initiated. One week after
hospitalization, arrhythmia resolved somewhat and DC
became unnecessary. This is when the decision for DNAR,
including that related to DC, was decided on. Despite
these improvements, pneumonia and respiratory discom-
fort worsened, and the patient had difficulty speaking. Al-
though nutritional intake was achieved with intravenous
drip, transfusion was difficult due to heart failure, leading
to malnutrition. Despite the prohibition of meals, the eld-
est daughter fed her mother on several occasions. Allevi-
ation of respiratory discomfort was considered but not
carried out due to the risk of death from reduced blood
pressure. The eldest daughter, who observed her mother
gasping and suffering, strongly requested artificial respir-
ation. After this, the patient responded to anti-microbials,
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The treatment strategy was discussed with the eldest
daughter again, and she agreed to forgo the use of an artifi-
cial respirator. The patient recovered thereafter, and in ac-
cordance with the eldest daughter’s wishes, a gastrostoma
was inserted. The patient suddenly died three days later
due to suffocation from aspiration. This entire process
spanned 9 weeks. If treatment subsequent to the second
DC was not carried out, the patient was thought to have
lived for only one week.
Actions and judgments, and their reasons
In this case, there were many opinions regarding life-
prolonging treatments, and the case provider questioned
what the attending physician and patient’s family consid-
ered to be life-prolonging treatments. The actions and
judgments of those involved were organized below.
Attending physician: Although I have somewhat nega-
tive views on life-prolonging treatments such as anti-
microbials, artificial respirators, and DC, I do carry out
treatments for heart failure to some extent, as it is my
specialty.
Patient: No capacity to make decisions.
Eldest daughter: I know what my mother’s wishes are. I
want her to live as long as possible, for my sake as well
as her own.
Second daughter: I feel that DC and artificial respir-
ation are painful for my mother, and I feel sorry for her.
Resident physician: I question why the attending physician
didn’t use anti-microbials, and whether that represents a
life-prolonging treatment. How about other treatments?
What makes a treatment a life-prolonging treatment?
Next, we organized what those involved considered to
be life-prolonging treatments, as well as the underlying
reasons.
 Anti-microbials were considered a life-prolonging
treatment to the attending physician because, al-
though he likely intended to begin treatment for
heart failure before pneumonia, anti-microbials were
non-essential and non-urgent. Other treatments car-
ried out at hospitalization were emergency treat-
ments for rescue and pain relief, so were not
considered life-prolonging treatments.
 To the attending physician, the first DC was an
emergency measure before the family’s consent for
DNAR was obtained, so it was not a life-prolonging
treatment. However, DCs subsequent to the second
one only increased suffering, and since heart failure
could not be completely cured or controlled and
death was imminent, they were life-prolonging
treatments. The use of a strong anti-arrhythmic
agent when continuing DC after the twentieth time
was not considered a life-prolonging treatmentbecause it was a measure associated with less suffer-
ing than DC, and was used for pain relief.
 According to the second daughter, DCs subsequent
to the second DC only prolonged suffering until
death, so were life-prolonging treatments.
 However, to the eldest daughter, the treatments held
promise up to the time that DC became unnecessary
one week post-admission, and since the other treat-
ments were for alleviating pain and curing the patient,
they were not life-prolonging treatments.
 To the attending physician, regardless of the
difficulty of curing the condition with an artificial
respirator, once the patient is on the respirator, it
cannot be easily discontinued due to legal concerns,
so it is a life-prolonging treatment.
 To the second daughter as well, since the artificial
respirator cannot cure her mother and prolongs
her suffering until death, it is a life-prolonging
treatment.
 Although the eldest daughter at first agreed not to
intubate the patient one week post-admission, she
strongly desired artificial respiration when the patient
began to exhibit signs of respiratory discomfort. Since
this measure relieves the patient from pain, she did
not consider it a life-prolonging treatment.
 The anti-microbial agent used concurrently with the
initiation of artificial respiration may not necessarily
be a life-prolonging treatment in the sense that the
eldest daughter strongly desired it. Yet, the attending
physician himself likely considered it a life-
prolonging treatment.
 The decision not to re-intubate once taken off the
artificial respirator was likely because, to the eldest
daughter as well, it would prolong the patient’s suf-
fering. Thus, it is a life-prolonging treatment.
 To the eldest daughter, the gastrostoma was inserted
to prevent pneumonia, allow for nutritional intake,
and for discharge from the hospital, and was thus
considered a treatment to cure her mother’s
condition. However, to the second daughter, since it
was an unnecessary invasive treatment at the
terminal stage, it was a life-prolonging treatment.
The attending physician did not necessarily see it as
a life-prolonging treatment, given the possibility of
home care in a state of reduced activity.
Since the effects of treatment and chances of death were
uncertain, participants indicated that whether a treatment
is life-prolonging should not be judged based on the end
result, but rather according to the intentions behind carry-
ing out the treatments. They also noted the troubles ari-
sing from the different meanings the treatments had to
those involved, such as rescue, life-prolonging, pain relief,
curing, and prevention.
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Based on the discussion above, participants summarized
the conditions for life-prolonging treatments as follows:
 A treatment that is carried out regardless of the
possibility of healing and death is imminent
(although there is some uncertainty).
 Suffering is severe.
 When patients consider the treatment to be futile
themselves, and the family and healthcare team
agree.
 When its futility is socially accepted.
Participants observed that decisions were influenced
by the family’s opinions and opinions of others that
comport with the social status of patients. With ad-
vances in life-prolonging technology, it is also becoming
clear that there are situations when such treatments are
futile at the terminal stage of an elderly person’s life. Yet,
in the past, both society and physicians were of the
mindset that life-sustaining treatments should be per-
formed until the very last moment. In this case, given
that the opinions of the patient, the family, and health-
care professionals differed, and that a stable social
awareness was not achieved, participants indicated the
need to increase social recognition of what futile life-
prolonging treatments are. Although therapy generally
aims to stop the worsening of a condition and im-
prove it, this is not the full picture. Instead, therapy
also encompasses emergency aid, pain relief, preven-
tion, and life-prolonging for the sole purpose of pre-
venting death. Thus, at some point, emergency aid
procedures may be considered life-prolonging proce-
dures. Although not recognized by patients, families,
and the general public, there are situations where life-
prolonging treatments and palliative treatments are
incompatible. Participants agreed that for each of
these situations, the objective of a particular treat-
ment must be clearly explained to those involved, and
the therapeutic effects and potential side effects suf-
ficiently discussed, with treatments carried out by
maintaining an appropriate balance. It was also pro-
posed that the phrase “life-prolonging treatment” should
not be used lightly, and when carrying out such treat-
ments, healthcare professionals should aim for social
consensus building when it comes to withholding or
discontinuing these treatments.
The 2nd NSD forum
In this group, 17 case studies were provided regarding
the question “What is a life-prolonging treatment?” The
following case was chosen to address the question of
how healthcare professionals should proceed when a pa-
tient strongly desires treatment until the very end.Case 2: A patient who strongly desires chemotherapy to the
greatest extent
Case source Nurse
Summary The patient was a 50-year-old male with
chronic leukemia. Onset was about six years ago, and he
had been visiting the hospital ever since. He was eventu-
ally hospitalized for chemotherapy and thereafter contin-
ued the routine of repeated hospitalization and home
care. While chemotherapy dramatically reduces the size
of enlarged lymph nodes and the spleen, bodily damage
also increases with dosage escalation. For the first few
months, the patient recuperated at home, but this grad-
ually decreased to one month, then to one week, and
after about one year, he could not be discharged from
the hospital. Although the patient knew that a complete
recovery was unlikely, chemotherapy was having an ef-
fect, thus both he and his wife desired continued treat-
ment. When the effects finally began to wane, and it
became difficult to predict whether bodily damage or
the curative effects would be greater, he was told that he
had about one month to live if therapy was discontin-
ued. To the patient, choosing to discontinue chemother-
apy was tantamount to giving into death, and thus he
desired, as a last resort, to undergo aggressive treatment
in a sterile room. Although the attending physician and I
doubted the wisdom in carrying out chemotherapy, the
disease specialist suggested that the choice be left to the
patient. Since the specialist’s opinion was prioritized over
the attending physician’s opinion within the medical team,
chemotherapy was initiated. Even among the nurses, there
were differing views on whether the therapy should be
carried out. The patient experienced delirium and panic
due to limited freedom in the sterile room. Yet, the
healthcare team, in collaboration with the psychiatric de-
partment and palliative care team, provided care to main-
tain the patient’s life, as well as care for the wife. The
treatment was covered by insurance. We were also able to
secure a bed in the sterile room without issues. One
month after initiating treatment, the patient desired fur-
ther treatment, although he could not leave the sterile
room. However, this was no longer possible. Soon there-
after, he was transferred from the sterile room to a semi-
sterile room and his symptoms were controlled. At one
time, the patient asked “how much longer do I have?” Al-
though the physician estimated about one month, he
responded that it depends on the person. At first, the pa-
tient asked “is it 3 years?”, to which the physician replied
“that’s difficult.” To this, the patient continued “1 year?”
“half a year?” “3 months?” For each of these, the physician
replied “that’s difficult.” After that, the patient stopped
asking, and seemed to have accepted the fact that death
was near. Although he no longer desired chemotherapy,
he proclaimed “now that I’ve heard that, I feel relieved,”
and that “I will try to bring about a miracle.” Regarding
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was risky given his enlarged cervical lymph nodes, the pa-
tient mentioned that since he could not decide himself,
the family should be consulted to make the decision. Al-
though his wife initially desired intubation, the patient’s
sister supported his shaken wife, and they eventually de-
cided on DNAR. The patient’s eldest son is independent
and lives far away from home. The patient’s sister ex-
plained the father’s condition to his teenage child. Al-
though the patient died a few weeks later, his wife
continued to slap his face throughout the night telling
him “don’t die yet.” In the end, the eldest son restrained
his mother. I believe that such cases will increase with ad-
vances in chemotherapy.
Actions and judgments, and their reasons
The participants summarized the case provider’s judg-
ment as follows: Although providing treatment as re-
quested by the patient is not necessarily a bad thing,
there remains the question of whether the treatment
should actually be carried out.
Participants considered the reasons for this judgment
as follows:
 The positive aspect is that treatment was carried out
to the greatest extent possible to fulfill the patient’s
wishes in accordance with his values.
 However, regarding the question of whether the
treatment was appropriate, the patient may have
been able to maintain a higher quality of life
(QOL) if the treatment was not carried out, e.g., he
may have been able to walk, go home, eat, and
lessen the burden of going to and from the
hospital.
 Carrying out an aggressive treatment confers the
risk of “therapeutic death.”
 In other words, although the patient’s judgment
comported with his values, it was not a rational
judgment based on careful consideration.
 Regarding the option of forgoing chemotherapy, this
option may not have been sufficiently explained to
the patient, and there may have been the lingering
thought that this option would be impossible to
communicate to the patient.
Life-prolonging treatment
Participants discussed what they consider to be life-
prolonging treatments, and their thoughts are summa-
rized below:
 Although not curative, it delays death, in the short-
or long-term.
 When the patient desires it, it cannot be considered
“futile.” It is a phrase commonly used when the patient does
not desire it, and when it seems futile or detrimental
to the patient from a third person’s perspective.
Given that one of the participants asserted that cancer
chemotherapy carried out as a non-curative treatment is
considered a life-prolonging treatment, the participants
discussed this issue and concluded that life-prolonging by
chemotherapy can either be long-term or short-term (i.e.,
due to a sharp deterioration in the patient’s condition).
Moreover, one might say that since the patient asked for a
life-prolonging treatment because he desired non-curative
chemotherapy until the very end, it was by no means “fu-
tile” because the patient was willing to fight the disease.
On the other hand, the patient left the decision of resusci-
tation to his family, who decided against it. In this respect,
it might be considered a “futile” life-prolonging treatment.
In any event, it was not possible to examine whether ther-
apy would be considered beneficial if the patient’s family
desires it in this particular case.
Participants also argued that there were issues regarding
discussions among healthcare professionals and the pa-
tient/family about treatment strategy. While the specialist
presented a choice between treatment and no treatment,
he did not recommend one over the other and left the
choice to the patient. Given the limited time for discus-
sions between the patient/family and healthcare team, the
patient kept to his decision for treatment. In order for the
patient and family to carefully consider options, in addition
to a need to be receptive to their anxiety, participants dis-
cussed the paternalism exhibited by the physicians. That is,
the physicians took on an excessive degree of responsibility
by keeping the patient from thinking about the decision be-
cause they could not deal with the patient’s anxiety, or by
holding back recommendations in order to avoid leading
them to a particular decision. Nurses also had no leeway
and team medicine was not being adequately performed.
There was also a shortage of interview rooms, and con-
sultation services within and outside the hospital were not
being fully introduced to the patient and his family. Partic-
ipants thus agreed that there was the inadequate psycho-
logical support and lack of coordination for obtaining
appropriate informed consent and carrying out the best
medical treatment.The 3rd NSD forum
In this group, 10 case studies were provided regarding
the question “What is a life-prolonging treatment?” We
chose the following case to illustrate judgments made by
a medical professional.Case 3: Treatment of a severely ill neonate
Case source Physician
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mid-20s visited the hospital due to threatened premature
labor. Therapy was unsuccessful and cesarean section
was performed. The infant was born at 23 weeks at less
than 600 g, received resuscitation therapy, and was ad-
mitted to the NICU. The infant was kept in an incubator
with artificial respiration and received hydration and nu-
trition drip infusion. While the survival rate of neonates
in this condition is usually about 30%, it exceeds 50% at
this hospital, so consent was obtained from the parents
after assuring them that the fullest effort will be made
with the aim of discharging the infant alive. Three days
later, an ultrasound exam revealed minor intracranial
bleeding, which worsened by day 4, at which hydroceph-
aly, disseminated intravascular coagulation (DIC), anemia,
and reduced blood pressure became apparent. Although
therapy was carried out with extensive transfusion and
blood products, multiple organ failure and anasarca pro-
gressed, and by about day 10, these conditions were con-
sidered irreversible. This decision was based on test data,
as well as the physician’s experience based on the infant’s
body color and activity. While I wanted to shift from ag-
gressive to palliative treatment, I could not get majority
approval at a conference regarding treatment strategy
from other physicians who had worked at the facility for
many years, although the supervising physician approved.
Thus, I could not discuss switching the treatment strategy
with the parents. In my view, treatment that exceeds the
healing capacity of the infant merely delays death, al-
though there were also opinions that a clear line could not
be drawn regarding what was considered excessive treat-
ment. Physicians also differed in opinion with respect to
how much blood to transfuse, and some thought that ad-
ministering anti-microbial agents without transfusion was
contradictory. In my view, it was not in the best interest of
the patient and family to continue aggressive treatment until
the infant worsened to a severely debilitated state. The par-
ents were always able to visit the infant, and either the father
or mother came once every day. I explained the infant’s con-
dition to them every time, at times together with the super-
vising physician, but the parents did not give their opinions
much or ask many questions. Explaining the specialized
therapy to the parents was difficult, particularly because
such explanations might convince the parents to discontinue
treatment. Thus, based on the unilateral judgment of the
physicians, treatment was continued, and the family did not
have the opportunity to voice their opinions. This, to me, is
what led to the life-prolonging treatment. On day 18, the in-
fant presented with pneumonia and anti-microbial treat-
ment was initiated, although it was already too late. It was
explained to the parents that sudden changes were possible,
but that treatment would be continued. On day 19, the in-
fant’s condition suddenly deteriorated, and after limited
chest compression, I explained to the parents the intent todiscontinue treatment, and the infant died. The infant was
discharged from the hospital to spend the final moments
with the family. The infant did not have any interactions
with grandparents.
Although other physicians thought that curing the in-
fant’s condition was difficult, they said nothing, and when
the infant died, they had the air of “so it didn’t work after
all…” They considered aggressive therapy their duty, and
given the difficulty of accepting death, they did not men-
tion the option of discontinuing treatment. However, phy-
sicians should not only set their minds to the continuation
of treatment, they should also think about the treatment’s
objective.
Actions and judgments, and their reasons
The participants summarized the case provider’s judg-
ment as follows: Not switching treatment strategy the
moment the infant’s condition became irreversible is
considered excessive treatment.
Participants considered the reasons for this judgment
as follows:
 During the course of treatment, there was no
medically-justifiable prospects for the infant‘s
recovery.
 Continuing aggressive treatment is cruel to the
patient because detrimental aspects far outweigh the
benefits. In that sense, discontinuing aggressive
treatment is not “giving up,” but rather is in the best
interest of the patient.
 Physicians only discussed strategy among themselves
and considered continuation of treatment to be the
best course of action, but did not explain this to the
parents or listen to their wishes.
The participants indicated that, although decision mak-
ing regarding treatment would be very difficult for the
family, the physicians only had aggressive treatment to the
last moment in mind, and believed that this was in the
family’s best interest. Yet, since different families have dif-
ferent values, the decision made by the physicians cannot
be considered appropriate.
The participants also discussed what was in the best
interest of the infant. At this stage, the infant exhibited
biological responses to pain and respiratory discomfort.
However, given that the nerves in the brain were still
underdeveloped, it was unclear whether the infant
could sense happiness and joy. It was also possible that
being embraced by the parents may have had a positive
influence. In sum, the participants concluded that al-
though the patient may not have had intentions, the
best interests of the patient should have been consid-
ered, keeping in mind the fact that the patient is a hu-
man being.
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Based on the discussion above, participants discussed
what they considered to be life-prolonging treatments,
and their thoughts are summarized below.
While life-prolonging treatment refers to a treatment
that sustains life, a life-prolonging treatment is consid-
ered futile when:
 The body is incurable and edging towards death.
 Detrimental effects (pain and suffering) outweigh
the benefits (healing and QOL) , and the patient
does not desire the treatment.
 However, despite the points above, losing sight of
the patient’s best interest, which is the objective of
healthcare, and aiming solely to delay death.
 Moreover, a treatment that would be detrimental to
the patient, even if it is pursued in consideration of
the family’s intentions.
The case provider indicated that when aggressive ther-
apy is the only objective, discontinuing it would be consid-
ered giving in. In this case, physicians will lose sight of the
objective when the condition becomes incurable and the
objective can no longer be accomplished. Participants also
discussed the parent’s intentions and agreed that while the
parent’s intentions should be considered, the patient’s best
interests should be the main consideration.
Discussion
The first forum discussed an elderly patient who lost the
ability to make decisions, the second forum discussed a
middle-aged patient who strongly desired treatment, and
the third forum discussed a case involving a neonate.
These case studies from hospitals illustrated various sit-
uations. We have summarized answers derived in the
forums with respect to “what is a futile life-prolonging
treatment” as discussed below.
What is futile life-prolonging treatment?
 A treatment carried out, without a reason other than
to prolong life, which is detrimental to the patient.
This judgment is made via the following process:
 Confirm that the patient does not desire it (refuses,
has no intention to undergo treatment, or prior
intention was unclear or does not exist),
 consider the family’s opinions,
 reach a consensus among the healthcare team, and
 obtain social acceptance.
This answer suggests that the decision of whether a life-
prolonging treatment is futile is made based on the purposeof treatment, whether it is effective, and the extent of its
benefits. This judgment also incorporates the patient’s in-
tent, family’s intent, consensus among healthcare profes-
sionals, and social acceptance. This answer, discussions
leading to the answer, and the significance of NSD, are dis-
cussed further below.
Futile life-prolonging treatments
The purpose of treatment and its effects and benefits
First, we discuss the purpose of treatment, as well as its
effects and benefits to the patient. The various objectives
of treatment should be specified, and the final objective
should be set as “the best interest of the patient.” NSD re-
vealed that recognition among those involved was lacking.
For instance, withholding anti-microbial agents in the first
case and continuing aggressive therapy in the third case
may have prevented the fulfillment of the patient’s best
interest due to the lack of awareness among physicians
regarding the objective of palliation. Palliative care is
gradually spreading in Japan, and neonatal end-of-life
healthcare guidelines were recently issued [18]. Yet,
when deciding on a treatment strategy, participants in-
dicated that since even one treatment can have mul-
tiple objectives to those involved, the degree of efficacy
and side effects for each objective, as well as the possi-
bility of inconsistencies among the objectives, should
be carefully considered. As in the second case, the pos-
sibility that a treatment would be in the patient’s best
interest regardless of its efficacy or side effects must
also be carefully considered. This is particularly im-
portant when making decisions on whether to carry out
treatments about which the opinions of those involved
are divided, such as the use of anti-microbial agents
and artificial hydration and nutrition, as well as resusci-
tation. In the first case, for example, although the treat-
ment being carried out when the patient suffocated in
the end was unknown, DNAR intentions should have
been reconsidered when she initially healed.
Uncertainty of therapeutic efficacy
Given the uncertainties surrounding therapeutic efficacy,
participants recognized through each NSD that it is diffi-
cult to judge the futility of treatments. There were dis-
crepancies in opinions among those involved, such as
patients and families who expect no limits to healing
and palliation by treatment, healthcare providers who at-
tempt aggressive treatment until chances of recovery are
near zero, and others involved who promptly give up on
healing and palliation. As in the first case, life-sustaining
measures, such as the use of artificial respirators, are a
controversial issue in Japan. For example, while such
measures are avoided in some cases, discontinuation is
not regulated by laws. This leads to hesitation and situa-
tions where beneficial treatments are not carried out, or
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Imminent death
Japanese guidelines on withholding or discontinuing life-
sustaining treatments are premised on the patient being
in the terminal stage and in a condition where there is
very little chance of improvement or long-term life
prolonging [7,20,21]. Answers derived in the first and
third forums also considered imminent death to be one
of the criteria for futile life-prolonging treatments. In
the second forum, the answer was that regardless of how
imminent death was and the degree of healing possible,
the bottom line was whether the treatment went against
the patient’s intentions and best interest. Since the pa-
tient desired treatment in the second case, we could not
evaluate the situation of when a patient does not desire
treatment. Thus, regardless of how imminent death is,
this answer suggests the possibility that the futility of a
treatment should also be considered based on whether a
patient refuses treatment, the best interest of the patient,
and whether the advanced wishes of a patient in an in-
curable condition, such as a vegetative state or severe
dementia, were known.
Process of judging whether a life-prolonging treatment
is futile
Informed consent
Here, we consider the process involved in judging treat-
ment objectives, and whether their effects are in the best
interest of the patient. NSD revealed that the patient’s in-
tentions should come first, and that the consensus of
those involved and social acceptance are also required.
Not desiring treatment (a criterion for futile treatments)
refers to situations such as when the patient refuses treat-
ment, when the patient loses the ability to make decisions
as in the first case, the existence of some type of advance
directive regarding treatment, when intentions are unclear,
or, as with the infant in the third case, when the patient
never had the ability to make decisions. According to par-
ticipants, what was lacking, first and foremost, was the ad-
equate provision of information and support for decision
making to patients with the ability to make decisions, and
to families of patients without this ability. They strongly
criticized the paternalism of healthcare professionals, and
indicated that the expansion of amenities for informed
consent is a social challenge.
Refusal of treatment
Although we could not address the situation arising
when a patient refuses treatment, discrepancies between
the opinions of those involved can potentially occur.
One such example is when a patient with the ability to
make decisions refuses life-prolonging treatment, buthealthcare professionals and the family consider the de-
crease in QOL from treatment to be within the permis-
sible range. While those involved should probably try to
convince the patient to undergo treatment and discuss
the patient’s desires and concerns, respecting the pa-
tient’s decision, not forcing the patient to undergo treat-
ment, and accepting the idea that the treatment is not in
the patient’s best interest given his/her refusal comports
with the answers derived from NSD. In such cases, while
the aspect of “refusal” is stronger than “futility,” “futile”
because of “refusal” might be accepted depending on the
degree to which those involved and society respect the
patient’s self-determination.
Representation based on advance directives
When a patient loses the ability to make decisions as in
the first case, the family’s opinion is given weight. It is gen-
erally considered ethically appropriate for the patient’s
family to make decisions as the patient’s representative if
advance directives exist, or if not, based on presumed in-
tent and the patient’s best interest [22]. While participants
had ethical concerns with the eldest daughter’s assertion
that “I know what my mother’s wishes are. I want her to
live as long as possible, for my sake as well as her own.” in
the first case, they did not go as far as requiring advance
directives or presumed intent. Notwithstanding, partici-
pants agreed that the eldest daughter desired the treat-
ment for healing and palliation, and concluded that the
final judgment of whether the treatment is futile should
require the eldest daughter’s consent. Indeed, the daugh-
ter’s request cannot be considered inappropriate, particu-
larly when considering the uncertainties of treatment and
its effects. Although there is no law regulating representa-
tion rights in the healthcare setting in Japan, the family
conventionally serves as the representative, and Japanese
guidelines also suggest obtaining consent from those in-
volved [7,20,21]. In the United States, where the hierarchy
of representative rights among those involved is deter-
mined by family consent laws, if a family member living
away from home requests that physicians perform life-
prolonging treatment, there are views that there is little
choice but to carry out the treatment when opinions differ
among children [23]. Accordingly, consent should have
been obtained from the eldest daughter as the patient’s
representative, and as indicated in the second case study,
healthcare workers should accept the eldest daughter’s
feelings and support her so that she could make a decision
from the patient’s standpoint. This also suggests that there
will be a need to further examine and understand the con-
cepts of advance directives and representation in Japan.
Representation based on best interest
When a patient never had the ability to make decisions
in the first place, as in the third case, participants agreed
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best interest [22]. In the third case, participants agreed
that the physician should have explained the treatment
strategy to the parents and took into consideration the
parents’ intentions. Yet, since the patient’s interests were
considered from the healthcare professional standpoint,
participants argued that healthcare professionals should
discuss strategy with parents in the event that they re-
quest treatments that contradict the patient’s best inter-
est. In the third case, since the parents followed the
healthcare professional’s treatment strategy, no situation
in which family and healthcare professionals have differ-
ing opinions was examined. Indeed, although objectively
judging the best interests of a patient who has no inten-
tions may be possible, if parents are in a position to rep-
resent the infant’s interests, then the parents’ decision
should be respected. While cases exist in Japan of treating
children after terminating parental rights when parents
refuse beneficial treatments for their children, treatments
are ordinarily carried out when life-sustaining treatments
are requested. The guidelines of the Japan Pediatric
Society stipulate that although guardians or healthcare
staff can propose the withholding or discontinuing of life-
sustaining treatments, discussions should be held with
both parties until they agree, and treatment should be
continued until then [18]. Thus, even when a patient lacks
the ability to make decisions to begin with, healthcare pro-
fessionals should provide recommendations on treatment
strategy, accept the family’s emotions, support and respect
their representative capacity, and should not discontinue
treatment if it goes against the family’s will.
Healthcare team consensus and social acceptance
There were differing views between physicians and nurses
in every case. Participants also agreed that more extensive
discussions on treatment strategy and consensus building
were necessary, although this seemed impossible based on
personnel and time constraints. When differing opinions
exist within the healthcare team or between the healthcare
team and patient/family, support should be sought exter-
nally. This relates to obtaining social acceptance, one of
the criteria of futile life-prolonging treatments. Partici-
pants indicated that patient consulting services serve as
such a medium, while government guidelines suggest
making use of the hospital ethics committee. In the three
cases discussed herein, an ethics committee was not con-
sulted and this was not suggested by participants either.
Moreover, excluding cases in which parental rights are ter-
minated, pre-rulings by courts are scarce in Japan, and
thus participants did not raise the possibility of using
court systems. Future challenges in Japanese healthcare
include team medicine, patient support, ethics committee
consultation, and pre-rulings by courts, and thus the en-
hancement of medical resources is necessary. On theother hand, resource constraints cannot be ignored, and
the futility of treatments have, in some instances, been ar-
gued in connection with medical cost cutting [9]. How-
ever, the criterion of social acceptance, as determined by
NSD, must be realized when withholding or discontinuing
treatments when it is the patient’s intention and in the pa-
tient’s best interest. This is not the case, however, when
judging whether a treatment is futile in light of the pa-
tient’s intentions or best interest. As discussed in the sec-
ond forum, in some instances, a beneficial treatment
desired by the patient is not covered by insurance or beds
may not be available in the sterile room, and thus treat-
ment cannot be provided. This implies that medical re-
sources are a social constraint imposed separately from
judgments of treatment futility.
Finally, we collectively evaluate NSD discussions and
answers derived therefrom as well as limitations of our
study. Discussions on medical futility in the United
States center on the fact that it is probable and influ-
enced by value judgments and the various objectives of
those involved. It is also something that physicians can-
not unilaterally judge, but rather is determined through
discussions and consensus among those involved. In this
context, resource availability is considered a separate
issue from futility [9]. Even participants who were un-
familiar with such arguments came to essentially the same
conclusion through NSD. By expressing the objective of
healthcare and the requirement of social acceptance, par-
ticipants were also able to elucidate issues related to the
awareness of those involved and the medical environment.
Answers obtained from NSD are similar to the end-of-life
guidelines in Japan in that they rely on achieving a con-
sensus among those involved. However, rather than being
limited to the terminal stage, the objective of treatment,
its effects, and benefits should be more specifically dis-
cussed with the patient’s intentions as the foremost con-
sideration. The family’s intentions come next, and the
healthcare professionals should not be making the final
decision.
As discussed above, however, the results of the NSD
forums need further examination regarding several points:
considering the futility of a treatment based on a patient’s
(advanced) will in the context of an incurable condition
regardless of how imminent death is; accepting futility
due to a patient’s refusal; implementing advance directives
and representation; handling a situation in which family
and healthcare professionals have differing opinions on
the treatment of a patient has no intentions; and adopting
effective measures for obtaining social acceptance when
discontinuing treatments according to a patient’s intention
and best interest.
The NSD method used in this study was qualitative with
a limited number of participants who were non-randomly
selected. So they could not represent any groups in society.
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current situation, and facilitation. The participants, how-
ever, were serious about collaboratively deliberating on the
issue. The results of their deliberation should therefore be
respected in the same way as results in sorts of forums for
participatory technology assessment with a limited number
of non-randomly selected participants.
In order to reduce bias in results of each NSD forum, we
also conducted three forums in different cities, compared
and summarized their results, and examined them by
reviewing relevant literature. Although we believe that
our summary of the study results is appropriate, add-
itional methods could have been planned to improve
credibility, such as transcribing IC records of the forums
into verbatim texts as well as sending an interim sum-
mary of each forum to its participants for authorization.
We, in fact, sent a research report and a draft manu-
script to participants who had shown willingness to re-
ceive the report on their consent forms at the end of the
funding period (March 2012). None of the participants
disagreed. Our study using the NSD method was condu-
cive to generating appropriate answers to the question
“What is life-prolonging treatment” and elucidating
problems in practice.
Conclusions
This small study contributed to elucidating the condi-
tions that underlie futile life-prolonging treatments
through NSD among participants of diverse backgrounds.
Such treatments are those carried out for the sole purpose
of prolonging life and are detrimental to the patient, and
should be decided based foremost on the patient’s lack of
desire for treatment, the consensus of those involved, and
through social acceptance. Current issues that surround
futile life-prolonging treatments in Japan were also eluci-
dated through NSD, including an awareness of the object-
ive of treatments and their effects, informed consent,
advance directives, decision making by representatives,
methods of social approval, and medical environment.
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